New drug trial aims to tame debilitating autoimmune Flare-Ups
NCT ID NCT07191444
Summary
This study will test whether a new drug called firsekibart works better than an existing treatment (anakinra) for controlling Adult-Onset Still's Disease. Researchers will enroll 20 adults with active disease to see which treatment more effectively reduces symptoms like fever and joint pain while lowering inflammation markers. The main goal is to see how many patients achieve disease inactivity after 24 weeks of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STILL'S DISEASE, ADULT-ONSET are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.